Back

Human-induced pluripotent stem cell cardiomyocytes for risk stratification of patients with LQT syndrome—ready for practice?

Cardiovascular Research

9 June 2026
Organised by: Logo
Read full article
ESC Journals ARRHYTHMIAS AND DEVICE THERAPY BASIC SCIENCE

Contributors

Thomas Eschenhagen
Thomas Eschenhagen

Author

The University Medical Center Hamburg-Eppendorf Hamburg , Germany

You may be interested in
thumbnail
Congress Presentation
Maturing hiPSC-cardiomyocytes in cardiac microtissues for accurate preclinical in vitro modelling of long-QT syndrome type 1
12 April 2024
thumbnail
Congress Session
Risk assessment and prevention of sudden cardiac death in cardiomyopathies
11 May 2024
thumbnail
Webinar
Induced-pluripotent stem cells (iPSC) technology for cardiac repair
17 March 2022
thumbnail
Congress Presentation
Estrogen-induced phenotype in hiPSC-derived cardiomyocytes of a woman affected by both Long QT Syndrome Type 2 and Polycystic Ovary Syndrome
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources